Tsung-Ying Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tsung-Ying Li has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Yung-Tsan Wu
Department of Physical Medicine and Rehabilitation, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei 11490, Taiwan
7 shared publications - King Hei Stanley Lam
13 Faculty of Medicine, The Chinese University of Hong Kong, New Territories, HKG
4 shared publications - Liang-Cheng Chen
Department of Physical Medicine and Rehabilitation, Tri-Service General Hospital, School of Medicine, National Defense Medical Center , Taipei, Taiwan
3 shared publications Liang‐Cheng Chen
Department of Physical Medicine and Rehabilitation Tri‐Service General Hospital School of Medicine National Defense Medical Center Taipei Taiwan ROC
3 shared publications- Shin-Tsu Chang
Department of Physical Medicine and Rehabilitation, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
3 shared publications - Yeu-Chin Chen
Hemophilia Care and Research Center, Tri-Service General Hospital, Taipei, Taiwan
3 shared publications
Latest Publications
- Open Access
- 1 April 2026
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 19, 1-7
Clinical Outcomes of Pregabalin Therapy in Adults with Type I Complex Regional Pain Syndrome: A Case Series
Background: Complex regional pain syndrome (CRPS) is a challenging pain disorder that may follow local trauma or central nervous system injury. Complex regional pain syndrome with identifiable nerve injury is classified as type II while cases without are classified as type I. Evidence regarding the effectiveness of pregabalin in treating complex regional pain syndrome remain limited. The study presents three cases of complex regional pain syndrome successfully treated with pregabalin. Methods: We retrospectively reviewed clinical data of patients diagnosed with complex regional pain syndrome at a single medical center in Taiwan between January 2022 and July 2025. Diagnosis was based on the Budapest criteria and confirmed with three-phase bone scintigraphy. Results: Three adult patients were included. All patients demonstrated clinical improvement in pain, quality of life, and rehabilitation adherence. One patient showed radiographic improvement on follow-up three-phase bone scan. Conclusion: Pregabalin appears to be a safe and potentially beneficial therapeutic option for complex regional pain syndrome and merits consideration as first-line pharmacotherapy within multidisciplinary treatment paradigms.
- 1 April 2026
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 19, 1-7
Open AccessClinical Outcomes of Pregabalin Therapy in Adults with Type I Complex Regional Pain Syndrome: A Case Series
Background: Complex regional pain syndrome (CRPS) is a challenging pain disorder that may follow local trauma or central nervous system injury. Complex regional pain syndrome with identifiable nerve injury is classified as type II while cases without are classified as type I. Evidence regarding the effectiveness of pregabalin in treating complex regional pain syndrome remain limited. The study presents three cases of complex regional pain syndrome successfully treated with pregabalin. Methods: We retrospectively reviewed clinical data of patients diagnosed with complex regional pain syndrome at a single medical center in Taiwan between January 2022 and July 2025. Diagnosis was based on the Budapest criteria and confirmed with three-phase bone scintigraphy. Results: Three adult patients were included. All patients demonstrated clinical improvement in pain, quality of life, and rehabilitation adherence. One patient showed radiographic improvement on follow-up three-phase bone scan. Conclusion: Pregabalin appears to be a safe and potentially beneficial therapeutic option for complex regional pain syndrome and merits consideration as first-line pharmacotherapy within multidisciplinary treatment paradigms.
- Open Access
- 30 August 2023
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 51 (8)
Successful transfemoral prosthesis in a patient with haemophilia A and factor VIII inhibitors: A case report
Haemophilia A patients who develop factor VIII inhibitors pose a challenge with respect to bleeding and orthopaedic management. This is particularly relevant in cases requiring amputation. We present here a case of a patient with severe haemophilia A and inhibitors who had a history of multiple surgeries due to periprosthetic joint infection and a non-healing wound which led to above-knee amputation. Following the implementation of appropriate and suitable transfemoral prosthesis and emicizumab therapy, the patient experienced a significant improvement in mobility and quality of life without any adverse events or bleeding episodes. Additional studies are required to more fully understand treatment options for lower limb amputations in the haemophilia population.
- 30 August 2023
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 51 (8)
Open AccessSuccessful transfemoral prosthesis in a patient with haemophilia A and factor VIII inhibitors: A case report
Haemophilia A patients who develop factor VIII inhibitors pose a challenge with respect to bleeding and orthopaedic management. This is particularly relevant in cases requiring amputation. We present here a case of a patient with severe haemophilia A and inhibitors who had a history of multiple surgeries due to periprosthetic joint infection and a non-healing wound which led to above-knee amputation. Following the implementation of appropriate and suitable transfemoral prosthesis and emicizumab therapy, the patient experienced a significant improvement in mobility and quality of life without any adverse events or bleeding episodes. Additional studies are required to more fully understand treatment options for lower limb amputations in the haemophilia population.
- 29 December 2022
- Published by Wiley in Haemophilia
- Vol. 29 (2) , 640-647
18F‐FDG PET/CT imaging for haemophilic arthropathy compared with clinical, radiological and power Doppler sonographic characteristics of 20 haemophilia patients
Introduction and objectives: Repeated joint bleeding in haemophilia patients may lead to haemophilic arthropathy with marked inflammation and synovitis. This study investigated the potential of 18F‐fluorodeoxyglucose positron emission tomography‐computed tomography (18F‐FDG PET/CT) as a novel diagnostic method for haemophilic arthropathy.Materials and methods: We recruited 20 adult haemophilia patients who reported history of hemarthroses in the shoulder, elbow, hip, knee, or ankle joints. All joints were assessed by power Doppler ultrasonography and radiography, and graded by hyperaemia score and Pettersson score, respectively. Joint pain was evaluated by visual analogue score (VAS). Range of motion (ROM), Haemophilia Joint Health Score (HJHS) and annual joint bleeding rate (AJBR) were recorded. Finally, all participants had whole‐body 18F‐FDG PET/CT, and maximum standardized uptake value (SUVmax) of the joints being studied was measured.Results: Thirteen patients had severe haemophilia, and seven had moderate haemophilia. The mean age was 36 years. PET SUVmax showed significant correlations with VAS, ROM, Pettersson score, hyperaemia score, HJHS score and AJBR in all large joints except hip. Joints with pain, hyperaemia and radiographic changes were found to have higher SUVmax than those without these features. Using Youden's index, the optimal cut‐off value for early radiographical arthropathy was found to be between 1.9 and 2.0.Conclusion: Our study indicates that 18F‐FDG PET/CT imaging correlated well with various conventional diagnostic techniques. It also demonstrated high sensitivity and specificity for early radiographic arthropathy. 18F‐FDG PET/CT imaging may quantitatively evaluate disease activity of most large joints in a single examination and help detect early haemophilic arthropathy.
- 29 December 2022
- Published by Wiley in Haemophilia
- Vol. 29 (2) , 640-647
18F‐FDG PET/CT imaging for haemophilic arthropathy compared with clinical, radiological and power Doppler sonographic characteristics of 20 haemophilia patients
Introduction and objectives: Repeated joint bleeding in haemophilia patients may lead to haemophilic arthropathy with marked inflammation and synovitis. This study investigated the potential of 18F‐fluorodeoxyglucose positron emission tomography‐computed tomography (18F‐FDG PET/CT) as a novel diagnostic method for haemophilic arthropathy.Materials and methods: We recruited 20 adult haemophilia patients who reported history of hemarthroses in the shoulder, elbow, hip, knee, or ankle joints. All joints were assessed by power Doppler ultrasonography and radiography, and graded by hyperaemia score and Pettersson score, respectively. Joint pain was evaluated by visual analogue score (VAS). Range of motion (ROM), Haemophilia Joint Health Score (HJHS) and annual joint bleeding rate (AJBR) were recorded. Finally, all participants had whole‐body 18F‐FDG PET/CT, and maximum standardized uptake value (SUVmax) of the joints being studied was measured.Results: Thirteen patients had severe haemophilia, and seven had moderate haemophilia. The mean age was 36 years. PET SUVmax showed significant correlations with VAS, ROM, Pettersson score, hyperaemia score, HJHS score and AJBR in all large joints except hip. Joints with pain, hyperaemia and radiographic changes were found to have higher SUVmax than those without these features. Using Youden's index, the optimal cut‐off value for early radiographical arthropathy was found to be between 1.9 and 2.0.Conclusion: Our study indicates that 18F‐FDG PET/CT imaging correlated well with various conventional diagnostic techniques. It also demonstrated high sensitivity and specificity for early radiographic arthropathy. 18F‐FDG PET/CT imaging may quantitatively evaluate disease activity of most large joints in a single examination and help detect early haemophilic arthropathy.
- Open Access
- 27 June 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (13) , 3705
The Effectiveness of Hydrodissection with 5% Dextrose for Persistent and Recurrent Carpal Tunnel Syndrome: A Retrospective Study
Patients with failure of primary surgery for carpal tunnel syndrome (CTS) present a frustrating clinical problem because there are no relevant treatment guidelines, and the effect of current conservative management or revision surgery is unsatisfactory. Hydrodissection with 5% dextrose is emerging as an effective treatment for primary CTS and may be an effective alternative treatment method for persistent or recurrent post-surgical CTS. We retrospectively investigated the long-term effectiveness of hydrodissection with 5% dextrose for persistent or recurrent CTS. Thirty-six of forty consecutively-treated patients with either persistent or recurrent symptoms of CTS after surgery, who were treated with ultrasound-guided hydrodissection of the median nerve using 10 mL of 5% dextrose, were available to provide outcome data by a structured phone interview at least six months after treatment completion. Symptom relief ≥ 50% represented an effective outcome, while symptom relief < 50% was rated as a poor outcome. Nearly 2/3 (61.1%) of patients reported an effective outcome after a mean of 3.1 injections, with a post-injection follow-up mean of 33 (6–67) months. A non-significant trend toward a more frequently-effective outcome was observed in those with recurrent versus persistent symptoms following CTS (76.9% vs. 52.2%, p = 0.165). However, a significantly higher percentage of those with recurrent symptoms reported an excellent outcome, defined as a greater than 70% improvement (8/13 [61.6%] vs. 3/23 [13%], p = 0.006). The percentage of patients achieving an effective outcome was not significantly different between 4 years of post-treatment follow-up (36.4% vs. 77.8% vs. 57.1%; p = 0.077). Hydrodissection with 5% dextrose may result in a clinically important and durable benefit in those experiencing persistent or recurrent CTS after surgery.
- 27 June 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (13) , 3705
Open AccessThe Effectiveness of Hydrodissection with 5% Dextrose for Persistent and Recurrent Carpal Tunnel Syndrome: A Retrospective Study
Patients with failure of primary surgery for carpal tunnel syndrome (CTS) present a frustrating clinical problem because there are no relevant treatment guidelines, and the effect of current conservative management or revision surgery is unsatisfactory. Hydrodissection with 5% dextrose is emerging as an effective treatment for primary CTS and may be an effective alternative treatment method for persistent or recurrent post-surgical CTS. We retrospectively investigated the long-term effectiveness of hydrodissection with 5% dextrose for persistent or recurrent CTS. Thirty-six of forty consecutively-treated patients with either persistent or recurrent symptoms of CTS after surgery, who were treated with ultrasound-guided hydrodissection of the median nerve using 10 mL of 5% dextrose, were available to provide outcome data by a structured phone interview at least six months after treatment completion. Symptom relief ≥ 50% represented an effective outcome, while symptom relief < 50% was rated as a poor outcome. Nearly 2/3 (61.1%) of patients reported an effective outcome after a mean of 3.1 injections, with a post-injection follow-up mean of 33 (6–67) months. A non-significant trend toward a more frequently-effective outcome was observed in those with recurrent versus persistent symptoms following CTS (76.9% vs. 52.2%, p = 0.165). However, a significantly higher percentage of those with recurrent symptoms reported an excellent outcome, defined as a greater than 70% improvement (8/13 [61.6%] vs. 3/23 [13%], p = 0.006). The percentage of patients achieving an effective outcome was not significantly different between 4 years of post-treatment follow-up (36.4% vs. 77.8% vs. 57.1%; p = 0.077). Hydrodissection with 5% dextrose may result in a clinically important and durable benefit in those experiencing persistent or recurrent CTS after surgery.
- Open Access
- 6 June 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (11) , 3241
Efficacy of a Novel Intra-Articular Administration of Platelet-Rich Plasma One-Week Prior to Hyaluronic Acid versus Platelet-Rich Plasma Alone in Knee Osteoarthritis: A Prospective, Randomized, Double-Blind, Controlled Trial
Recent studies have suggested that the combined injection of platelet-rich plasma (PRP) and hyaluronic acid (HA) may have additive benefits for knee osteoarthritis over PRP alone, but there is insufficient evidence to support this combined injection. Moreover, the simultaneous injection of PRP and HA may offset the combined effect. Hence, the aim of this prospective, randomized, double-blind study was to assess their combined efficacy with a novel injection protocol. Forty-six study subjects with unilateral knee osteoarthritis were randomized to receive either a single-dose injection of HA (intervention group) or normal saline (control group) 1 week after a single-dose injection of leukocyte-poor PRP. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and static balance and the risk of falls measured by Biodex Balance System were, respectively, the primary and secondary outcome measures. Evaluations were performed at baseline, 1 month, 3 months, 6 months, and 12 months post-injection. The intervention group exhibited significant declines in WOMAC pain, stiffness, and total scores, as well as static balance, compared to the control group (p < 0.05). These randomized double-blind control trials, with novel protocol of intra-articular injection of PRP 1-week prior to HA, provide greater symptom relief and improve static balance compared to PRP alone in patients with knee osteoarthritis.
- 6 June 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (11) , 3241
Open AccessEfficacy of a Novel Intra-Articular Administration of Platelet-Rich Plasma One-Week Prior to Hyaluronic Acid versus Platelet-Rich Plasma Alone in Knee Osteoarthritis: A Prospective, Randomized, Double-Blind, Controlled Trial
Recent studies have suggested that the combined injection of platelet-rich plasma (PRP) and hyaluronic acid (HA) may have additive benefits for knee osteoarthritis over PRP alone, but there is insufficient evidence to support this combined injection. Moreover, the simultaneous injection of PRP and HA may offset the combined effect. Hence, the aim of this prospective, randomized, double-blind study was to assess their combined efficacy with a novel injection protocol. Forty-six study subjects with unilateral knee osteoarthritis were randomized to receive either a single-dose injection of HA (intervention group) or normal saline (control group) 1 week after a single-dose injection of leukocyte-poor PRP. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and static balance and the risk of falls measured by Biodex Balance System were, respectively, the primary and secondary outcome measures. Evaluations were performed at baseline, 1 month, 3 months, 6 months, and 12 months post-injection. The intervention group exhibited significant declines in WOMAC pain, stiffness, and total scores, as well as static balance, compared to the control group (p < 0.05). These randomized double-blind control trials, with novel protocol of intra-articular injection of PRP 1-week prior to HA, provide greater symptom relief and improve static balance compared to PRP alone in patients with knee osteoarthritis.
- Open Access
- 1 March 2022
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 121 (3) , 582-591
Evolution of congenital haemophilia care in Taiwan
- 1 March 2022
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 121 (3) , 582-591
Open AccessEvolution of congenital haemophilia care in Taiwan
- 19 January 2022
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 23 (7) , 1249-1258
The Long-Term Analgesic Effectiveness of Platelet-Rich Plasma Injection for Carpal Tunnel Syndrome: A Cross-Sectional Cohort Study
Interest in perineural platelet-rich-plasma (PRP) injections for the treatment of carpal tunnel syndrome (CTS) has increased in recent years. However, evidence supporting the long-term effectiveness of PRP is lacking. Therefore, the aim of our cross-sectional cohort study was to investigate the long-term results of PRP injections for CTS. Eighty-one patients diagnosed with CTS of any grade who received a single PRP injection at least 2 years prior were enrolled. Through structured telephone interviews, all patients were asked of their post-injection outcomes compared to their pre-injection condition. Symptom relief ≥50%, compared to the pre-injection condition, was considered an effective outcome. Binary logistic regression was applied to analyze each baseline variable as a regressor for determining the prognostic outcome factors. In total, 70% of patients reported positive outcomes ≥2 years post-injection. Shorter duration of symptoms before treatment (odds ratio: 0.991; 95% confidence interval [CI] 0.983–0.999; P = .023) and lower electrodiagnostic severity of CTS were the main prognostic factors for an effective outcome (mild grade vs severe grade, odds ratio: 17.652; 95% CI 1.43–221.1; P = .025). Although there was a trend toward positive outcomes at longer follow-up durations (2–3 years vs 3–4 years vs 4–5 years), the difference was not statistically significant. A single perineural PRP injection has a long-term analgesic effect on CTS, especially in mild-to-moderate cases.
- 19 January 2022
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 23 (7) , 1249-1258
The Long-Term Analgesic Effectiveness of Platelet-Rich Plasma Injection for Carpal Tunnel Syndrome: A Cross-Sectional Cohort Study
Interest in perineural platelet-rich-plasma (PRP) injections for the treatment of carpal tunnel syndrome (CTS) has increased in recent years. However, evidence supporting the long-term effectiveness of PRP is lacking. Therefore, the aim of our cross-sectional cohort study was to investigate the long-term results of PRP injections for CTS. Eighty-one patients diagnosed with CTS of any grade who received a single PRP injection at least 2 years prior were enrolled. Through structured telephone interviews, all patients were asked of their post-injection outcomes compared to their pre-injection condition. Symptom relief ≥50%, compared to the pre-injection condition, was considered an effective outcome. Binary logistic regression was applied to analyze each baseline variable as a regressor for determining the prognostic outcome factors. In total, 70% of patients reported positive outcomes ≥2 years post-injection. Shorter duration of symptoms before treatment (odds ratio: 0.991; 95% confidence interval [CI] 0.983–0.999; P = .023) and lower electrodiagnostic severity of CTS were the main prognostic factors for an effective outcome (mild grade vs severe grade, odds ratio: 17.652; 95% CI 1.43–221.1; P = .025). Although there was a trend toward positive outcomes at longer follow-up durations (2–3 years vs 3–4 years vs 4–5 years), the difference was not statistically significant. A single perineural PRP injection has a long-term analgesic effect on CTS, especially in mild-to-moderate cases.
- Open Access
- 1 January 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 9745322
Novel Motor‐Sparing Ultrasound‐Guided Neural Injection in Severe Carpal Tunnel Syndrome: A Comparison of Four Injectates
Nerve hydrodissection uses fluid injection under pressure to selectively separate nerves from areas of suspected entrapment; this procedure is increasingly viewed as potentially useful in treating carpal tunnel syndrome (CTS). The usage of normal saline (NS), 5% dextrose water (D5W), platelet‐rich plasma (PRP), and hyaluronic acid (HA) as primary injectates for hydrodissection without an anesthetic can limit anesthetic‐related toxicity and preserve the motor functions of the median nerve. Here, we describe a novel motor‐sparing neural injection and compare the effect of these four injectates for severe CTS. We retrospectively reviewed the outcomes of 61 severe CTS cases after a single neural injection with NS, D5W, PRP, or HA. Outcomes were evaluated on the 1st and 6th months postinjection, including the Boston Carpal Tunnel Questionnaire (BCTQ) scores and the nerve cross‐sectional area (CSA). The results revealed that PRP, D5W, and HA were more efficient than NS at all measured time points (p < 0.05), except for CSA at the 1st month between the NS and D5W groups. Single‐injections of PRP and D5W seemed more effective than that of HA within 6 months postinjection for symptom and functional improvement (6th‐month BCTQ‐symptom, D5W vs. HA, p = 0.047; 1st‐month BCTQ‐symptom, PRP vs. HA, p = 0.018; 1st‐ and 6th‐month BCTQ‐function, D5W vs. HA, p = 0.002 and 0.016, respectively; 1st‐month BCTQ‐function, PRP vs. HA, p < 0.001). For reducing CSA, PRP and HA seemed more effective than D5W (HA > PRP > D5W on the 1st month and HA vs. D5W, p = 0.001; PRP > HA > D5W on the 6th month and PRP vs. D5W, p = 0.012).
- 1 January 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 9745322
Open AccessNovel Motor‐Sparing Ultrasound‐Guided Neural Injection in Severe Carpal Tunnel Syndrome: A Comparison of Four Injectates
Nerve hydrodissection uses fluid injection under pressure to selectively separate nerves from areas of suspected entrapment; this procedure is increasingly viewed as potentially useful in treating carpal tunnel syndrome (CTS). The usage of normal saline (NS), 5% dextrose water (D5W), platelet‐rich plasma (PRP), and hyaluronic acid (HA) as primary injectates for hydrodissection without an anesthetic can limit anesthetic‐related toxicity and preserve the motor functions of the median nerve. Here, we describe a novel motor‐sparing neural injection and compare the effect of these four injectates for severe CTS. We retrospectively reviewed the outcomes of 61 severe CTS cases after a single neural injection with NS, D5W, PRP, or HA. Outcomes were evaluated on the 1st and 6th months postinjection, including the Boston Carpal Tunnel Questionnaire (BCTQ) scores and the nerve cross‐sectional area (CSA). The results revealed that PRP, D5W, and HA were more efficient than NS at all measured time points (p < 0.05), except for CSA at the 1st month between the NS and D5W groups. Single‐injections of PRP and D5W seemed more effective than that of HA within 6 months postinjection for symptom and functional improvement (6th‐month BCTQ‐symptom, D5W vs. HA, p = 0.047; 1st‐month BCTQ‐symptom, PRP vs. HA, p = 0.018; 1st‐ and 6th‐month BCTQ‐function, D5W vs. HA, p = 0.002 and 0.016, respectively; 1st‐month BCTQ‐function, PRP vs. HA, p < 0.001). For reducing CSA, PRP and HA seemed more effective than D5W (HA > PRP > D5W on the 1st month and HA vs. D5W, p = 0.001; PRP > HA > D5W on the 6th month and PRP vs. D5W, p = 0.012).
- 31 July 2019
- Published by Wiley in Journal of Tissue Engineering and Regenerative Medicine
- Vol. 13 (11) , 2009-2017
Comparison of perineural platelet‐rich plasma and dextrose injections for moderate carpal tunnel syndrome: A prospective randomized, single‐blind, head‐to‐head comparative trial
Recent studies demonstrated the utility of perineural injection with platelet-rich plasma (PRP) and 5% dextrose (D5W) as novel strategies for treatment of carpal tunnel syndrome (CTS). The present study comprised a prospective, randomized, single-blind, head-to head comparative trial to compare the 6-month outcome of perineural injection with PRP or D5W in patients with moderate CTS. Fifty-two patients with unilateral moderate CTS were enrolled and randomized into two groups: The PRP group received a single 3-cc perineural injection of PRP under ultrasound guidance, and dextrose group received a single 3-cc perineural injection of D5W under ultrasound guidance. The Boston Carpal Tunnel Syndrome Questionnaire score was used as the primary outcome. Secondary outcomes included cross-sectional area (CSA) of the median nerve and electrophysiological assessments. Evaluations were performed at baseline and at 1, 3, and 6 months postinjection. All patients (26 patients per group) completed the study. Compared with the dextrose group, the PRP group demonstrated significant reductions in Boston Carpal Tunnel Syndrome Questionnaire function at 3 months (p = .044), distal motor latency at 6 months (p = .028), and CSA at 3 and 6 months (p = .010 and.018, respectively). A single perineural injection of PRP reduced the CSA of the median nerve more effectively than injection of D5W at 3 and 6 months postinjection for patients with moderate CTS.
- 31 July 2019
- Published by Wiley in Journal of Tissue Engineering and Regenerative Medicine
- Vol. 13 (11) , 2009-2017
Comparison of perineural platelet‐rich plasma and dextrose injections for moderate carpal tunnel syndrome: A prospective randomized, single‐blind, head‐to‐head comparative trial
Recent studies demonstrated the utility of perineural injection with platelet-rich plasma (PRP) and 5% dextrose (D5W) as novel strategies for treatment of carpal tunnel syndrome (CTS). The present study comprised a prospective, randomized, single-blind, head-to head comparative trial to compare the 6-month outcome of perineural injection with PRP or D5W in patients with moderate CTS. Fifty-two patients with unilateral moderate CTS were enrolled and randomized into two groups: The PRP group received a single 3-cc perineural injection of PRP under ultrasound guidance, and dextrose group received a single 3-cc perineural injection of D5W under ultrasound guidance. The Boston Carpal Tunnel Syndrome Questionnaire score was used as the primary outcome. Secondary outcomes included cross-sectional area (CSA) of the median nerve and electrophysiological assessments. Evaluations were performed at baseline and at 1, 3, and 6 months postinjection. All patients (26 patients per group) completed the study. Compared with the dextrose group, the PRP group demonstrated significant reductions in Boston Carpal Tunnel Syndrome Questionnaire function at 3 months (p = .044), distal motor latency at 6 months (p = .028), and CSA at 3 and 6 months (p = .010 and.018, respectively). A single perineural injection of PRP reduced the CSA of the median nerve more effectively than injection of D5W at 3 and 6 months postinjection for patients with moderate CTS.
- 13 March 2019
- Published by Wiley in Haemophilia
- Vol. 25 (3) , 484-492
An exploratory comparison of single intra‐articular injection of platelet‐rich plasma vs hyaluronic acid in treatment of haemophilic arthropathy of the knee
Introduction: Intra‐articular platelet‐rich plasma (PRP) injection therapy has been extensively applied in clinical practice to treat musculoskeletal disorders such as osteoarthritis, but the treatment for haemophilic arthropathy is rarely reported.Aims: This study aimed to compare the efficacy of intra‐articular PRP vs hyaluronic acid (HA) injections in treating haemophilic arthropathy of knee joints.Patients: Twenty‐two haemophilia patients (mean age, 41.1 ± 1.7 [range, 20‐50] years) with painful haemophilic arthropathy of the knee were enrolled for this open‐label and observer‐blind study.Methods: Eleven patients were treated with a single intra‐articular injection of PRP and the other 11 received five consecutively weekly intra‐articular injections of HA. Outcome assessment included pain by visual analogue scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Chinese Version and synovial change determined by ultrasonography.Results: Platelet‐rich plasma and HA intra‐articular injection showed statistically significant reduction in VAS, WOMAC total score and hyperaemia score from baseline to 6‐month post‐treatment. Inter‐group comparison showed statistically significant difference in the change in VAS score, WOMAC pain score, physical function score and total score at 6 months, wherein PRP group showed sustained beneficial effect than HA group at 6 months.Conclusion: Our study demonstrates that, in comparison with five weekly injections of HA, a single PRP injection resulted in better improvement in pain relief and knee joint function, and greater reduction in synovial hyperaemia for up to 6 months. Our results suggest that PRP may be practical and effective for haemophilic knee arthropathy, and further investigation is warranted.
- 13 March 2019
- Published by Wiley in Haemophilia
- Vol. 25 (3) , 484-492
An exploratory comparison of single intra‐articular injection of platelet‐rich plasma vs hyaluronic acid in treatment of haemophilic arthropathy of the knee
Introduction: Intra‐articular platelet‐rich plasma (PRP) injection therapy has been extensively applied in clinical practice to treat musculoskeletal disorders such as osteoarthritis, but the treatment for haemophilic arthropathy is rarely reported.Aims: This study aimed to compare the efficacy of intra‐articular PRP vs hyaluronic acid (HA) injections in treating haemophilic arthropathy of knee joints.Patients: Twenty‐two haemophilia patients (mean age, 41.1 ± 1.7 [range, 20‐50] years) with painful haemophilic arthropathy of the knee were enrolled for this open‐label and observer‐blind study.Methods: Eleven patients were treated with a single intra‐articular injection of PRP and the other 11 received five consecutively weekly intra‐articular injections of HA. Outcome assessment included pain by visual analogue scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Chinese Version and synovial change determined by ultrasonography.Results: Platelet‐rich plasma and HA intra‐articular injection showed statistically significant reduction in VAS, WOMAC total score and hyperaemia score from baseline to 6‐month post‐treatment. Inter‐group comparison showed statistically significant difference in the change in VAS score, WOMAC pain score, physical function score and total score at 6 months, wherein PRP group showed sustained beneficial effect than HA group at 6 months.Conclusion: Our study demonstrates that, in comparison with five weekly injections of HA, a single PRP injection resulted in better improvement in pain relief and knee joint function, and greater reduction in synovial hyperaemia for up to 6 months. Our results suggest that PRP may be practical and effective for haemophilic knee arthropathy, and further investigation is warranted.